Last reviewed · How we verify
antiviral therapy
Antiviral therapy inhibits viral replication by targeting viral enzymes or proteins essential for the virus lifecycle.
Antiviral therapy inhibits viral replication by targeting viral enzymes or proteins essential for the virus lifecycle. Used for Viral infections (specific indication not specified).
At a glance
| Generic name | antiviral therapy |
|---|---|
| Also known as | Combivir |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Antiviral drugs work through multiple mechanisms depending on the specific agent and target virus, including inhibition of viral polymerases, proteases, or reverse transcriptases that are critical for viral reproduction. By blocking these viral-specific enzymes or proteins, antivirals prevent the virus from replicating within host cells and reduce viral load. This allows the immune system to better control the infection and reduces disease severity and transmission.
Approved indications
- Viral infections (specific indication not specified)
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
Key clinical trials
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (PHASE3)
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
- T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation (PHASE1)
- A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antiviral therapy CI brief — competitive landscape report
- antiviral therapy updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI